Markers of Metabolic Syndrome in Patients with Pituitary Adenoma: A Case Series of 303 Patients

 

 Permissions and Reprints

Abstract

To assess the demographic characteristics and hormonal status of patients who presented to our clinic with pituitary adenoma and to demonstrate the presence, prevalence, and relationship of metabolic syndrome parameters in these patients. The study included 303 patients with known or newly diagnosed pituitary adenoma and 52 age- and sex-matched healthy controls. The patients were classified into 3 groups; acromegaly (ACRO) (n=54),prolactinoma (PRLoma) (n=163), and non-functional adenoma (NFA) (n=86). in 55.6% (n=172) and 52% (n=163) of the patients, respectively. The waist circumference of all patients (p<0.001) and body mass index (BMI) of patients with PRLoma (p=0.03) and ACRO (p<0.001) were found to be significantly higher than in the controls. The HbA1c, insulin and HOMA-IR values were significantly higher in the ACRO and PRLoma groups, whereas the insulin and HOMA-IR values were significantly higher in the NFA group compared with the control group (p<0.001 and p<0.001, respectively). When the 3 patient groups were compared, waist circumference and BMI were significantly higher in the ACRO group than in the PRLoma group (p=0.04 and p=0.03, respectively). In patients developing pituitary failure after treatment, age, waist circumference, plasma glucose, low-density lipoproteins and triglyceride values were significantly increased when compared with those without pituitary failure after treatment (p<0.001). In our study, it was found that there was increased metabolic and cardiovascular risk in functional pituitary adenoma and NFA.

• References

• 1 Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96: 1633-1641
  CrossrefPubMedGoogle Scholar
• 2 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613-619
  CrossrefPubMedGoogle Scholar
• 3 Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1987; 16: 586-608
  PubMedGoogle Scholar
• 4 Nielsen EH, Lindholm J, Laurberg P. et al Nonfunctioning pituitary adenoma: Incidence, causes of death and quality of life in relation to pituitary function. Pituitary 2007; 10: 67-73
  CrossrefPubMedGoogle Scholar
• 5 Tomlinson JW, Holden N, Hills RK. et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425-431
  CrossrefPubMedGoogle Scholar
• 6 Davis FG, Kupelian V, Freels S. et al. Prevalence esti- mates for primary brain tumors in the United States by behavior and major histology groups. J Neurooncol 2001; 3: 152-158
  PubMedGoogle Scholar
• 7 Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
  CrossrefPubMedGoogle Scholar
• 8 Dekkers OM, Biermasz NR, Pereira AM. et al. Mortality in acromegaly: A metaanalysis. J Clin Endocrinol Metab 2008; 93: 61-67
  CrossrefPubMedGoogle Scholar
• 9 Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34: 1429-1433
  CrossrefPubMedGoogle Scholar
• 10 Neely RD, Rooney DP, Bell PM. et al. Influence of growth hormone on glucose-glucose 6-phosphate cycle and insulin action in normal humans. Am J Physiol 1992; 263 (5 Pt 1) E980-E987
  PubMedGoogle Scholar
• 11 Alexopoulou O, Bex M, Kamenicky P. et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients. Pituatry 2014; 17: 81-89
  PubMedGoogle Scholar
• 12 Pivonello R, Auriemma RS, Ludovica FS. et al. Complications of acromegaly: Cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017; 20: 46-62
  CrossrefPubMedGoogle Scholar
• 13 Van der Klaauw AA, Biermasz NR, Feskens EJ. et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 2007; 156: 455-462
  CrossrefPubMedGoogle Scholar
• 14 Doğan BA, Tuna MM, Arduç A. et al. Increased risk of unfavorable metabolic outcome in patients with clinically nonfunctioning pituitary adenomas. Horm Metab Res 2015; 47: 652-665
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Joustra SD, KMJA Claessen, Dekkers OM. et al. Biermasz high prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenoma. Plos One 2014; 9: 3
  PubMedGoogle Scholar
• 16 Van Bunderen CC, van Varsseveld NC, Heymans MW. et al. Effect of long-term GH replacement therapy on cardiovascular out- comes in GH-deficient patients previously treated for acromegaly: A sub-analysis from the Dutch National Registry of Growth Hor- mone Treatment in Adults. Eur J Endocrinol 2014; 171: 717-726
  CrossrefPubMedGoogle Scholar
• 17 Melmed S. Acromegaly. N Engl J Med 1990; 322: 966-977
  CrossrefPubMedGoogle Scholar
• 18 Roelfsema F, Frolich M, Geelhoed-Duyvestijn PH. et al. Glucagon-stimulated plasma C-peptide and insulin levels in active and non-active acrome- galics. Clin Endocrinol (Oxf) 1985; 23: 627-634
  CrossrefPubMedGoogle Scholar
• 19 Berinder K, Nystrom T, Hoybye C. et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207
  CrossrefPubMedGoogle Scholar
• 20 Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009; 12: 96-104
  CrossrefPubMedGoogle Scholar
• 21 Ben-Jonathan N, Hugo E, Brandebourg TD. et al. Focus on prolactin as a metabolichormone. Trends Endocrinol Metab 2006; 17: 110-116
  CrossrefPubMedGoogle Scholar